Literature DB >> 29119601

An integrative approach to assess X-chromosome inactivation using allele-specific expression with applications to epithelial ovarian cancer.

Nicholas B Larson1, Zachary C Fogarty1, Melissa C Larson1, Kimberly R Kalli2, Kate Lawrenson3,4, Simon Gayther4, Brooke L Fridley5, Ellen L Goode6, Stacey J Winham1.   

Abstract

X-chromosome inactivation (XCI) epigenetically silences transcription of an X chromosome in females; patterns of XCI are thought to be aberrant in women's cancers, but are understudied due to statistical challenges. We develop a two-stage statistical framework to assess skewed XCI and evaluate gene-level patterns of XCI for an individual sample by integration of RNA sequence, copy number alteration, and genotype data. Our method relies on allele-specific expression (ASE) to directly measure XCI and does not rely on male samples or paired normal tissue for comparison. We model ASE using a two-component mixture of beta distributions, allowing estimation for a given sample of the degree of skewness (based on a composite likelihood ratio test) and the posterior probability that a given gene escapes XCI (using a Bayesian beta-binomial mixture model). To illustrate the utility of our approach, we applied these methods to data from tumors of ovarian cancer patients. Among 99 patients, 45 tumors were informative for analysis and showed evidence of XCI skewed toward a particular parental chromosome. For 397 X-linked genes, we observed tumor XCI patterns largely consistent with previously identified consensus states based on multiple normal tissue types. However, 37 genes differed in XCI state between ovarian tumors and the consensus state; 17 genes aberrantly escaped XCI in ovarian tumors (including many oncogenes), whereas 20 genes were unexpectedly inactivated in ovarian tumors (including many tumor suppressor genes). These results provide evidence of the importance of XCI in ovarian cancer and demonstrate the utility of our two-stage analysis.
© 2017 WILEY PERIODICALS, INC.

Entities:  

Keywords:  Bayesian; RNA-Seq; mixture model; ovarian cancer

Mesh:

Substances:

Year:  2017        PMID: 29119601      PMCID: PMC5726546          DOI: 10.1002/gepi.22091

Source DB:  PubMed          Journal:  Genet Epidemiol        ISSN: 0741-0395            Impact factor:   2.135


  47 in total

1.  Decreased expression of Kallmann syndrome 1 sequence gene (KAL1) contributes to oral squamous cell carcinoma progression and significantly correlates with poorly differentiated grade.

Authors:  Jiannan Liu; Wei Cao; Wantao Chen; Liqun Xu; Chenping Zhang
Journal:  J Oral Pathol Med       Date:  2014-07-24       Impact factor: 4.253

2.  XCI-escaping gene KDM5C contributes to ovarian development via downregulating miR-320a.

Authors:  Yi-Xi Sun; Yi-Xin Zhang; Dan Zhang; Chen-Ming Xu; Song-Chang Chen; Jun-Yu Zhang; Ye-Chun Ruan; Feng Chen; Run-Ju Zhang; Ye-Qing Qian; Yi-Feng Liu; Lu-Yang Jin; Tian-Tian Yu; Hai-Yan Xu; Yu-Qin Luo; Xin-Mei Liu; Fei Sun; Jian-Zhong Sheng; He-Feng Huang
Journal:  Hum Genet       Date:  2016-11-28       Impact factor: 4.132

3.  Relationship of XIST expression and responses of ovarian cancer to chemotherapy.

Authors:  Kuan-Chun Huang; Pulivarthi H Rao; Ching C Lau; Edith Heard; Shu-Kay Ng; Carolyn Brown; Samuel C Mok; Ross S Berkowitz; Shu-Wing Ng
Journal:  Mol Cancer Ther       Date:  2002-08       Impact factor: 6.261

4.  Potential role of the inactivated X chromosome in ovarian epithelial tumor development.

Authors:  P C Cheng; J A Gosewehr; T M Kim; M Velicescu; M Wan; J Zheng; J C Felix; K F Cofer; P Luo; B H Biela; G Godorov; L Dubeau
Journal:  J Natl Cancer Inst       Date:  1996-04-17       Impact factor: 13.506

5.  Landscape of X chromosome inactivation across human tissues.

Authors:  Taru Tukiainen; Alexandra-Chloé Villani; Angela Yen; Manuel A Rivas; Jamie L Marshall; Rahul Satija; Matt Aguirre; Laura Gauthier; Mark Fleharty; Andrew Kirby; Beryl B Cummings; Stephane E Castel; Konrad J Karczewski; François Aguet; Andrea Byrnes; Tuuli Lappalainen; Aviv Regev; Kristin G Ardlie; Nir Hacohen; Daniel G MacArthur
Journal:  Nature       Date:  2017-10-11       Impact factor: 49.962

6.  Comparative proteomic profiling of triple-negative breast cancer reveals that up-regulation of RhoGDI-2 is associated to the inhibition of caspase 3 and caspase 9.

Authors:  Marcos A Muñiz Lino; Yadira Palacios-Rodríguez; Sergio Rodríguez-Cuevas; Verónica Bautista-Piña; Laurence A Marchat; Erika Ruíz-García; Horacio Astudillo-de la Vega; Ana E González-Santiago; Ali Flores-Pérez; José Díaz-Chávez; Ángeles Carlos-Reyes; Elizbeth Álvarez-Sánchez; César López-Camarillo
Journal:  J Proteomics       Date:  2014-04-22       Impact factor: 4.044

7.  The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma.

Authors:  Pedro A Pérez-Mancera; Alistair G Rust; Louise van der Weyden; Glen Kristiansen; Allen Li; Aaron L Sarver; Kevin A T Silverstein; Robert Grützmann; Daniela Aust; Petra Rümmele; Thomas Knösel; Colin Herd; Derek L Stemple; Ross Kettleborough; Jacqueline A Brosnan; Ang Li; Richard Morgan; Spencer Knight; Jun Yu; Shane Stegeman; Lara S Collier; Jelle J ten Hoeve; Jeroen de Ridder; Alison P Klein; Michael Goggins; Ralph H Hruban; David K Chang; Andrew V Biankin; Sean M Grimmond; Lodewyk F A Wessels; Stephen A Wood; Christine A Iacobuzio-Donahue; Christian Pilarsky; David A Largaespada; David J Adams; David A Tuveson
Journal:  Nature       Date:  2012-04-29       Impact factor: 49.962

8.  Derivation of consensus inactivation status for X-linked genes from genome-wide studies.

Authors:  Bradley P Balaton; Allison M Cotton; Carolyn J Brown
Journal:  Biol Sex Differ       Date:  2015-12-30       Impact factor: 5.027

9.  Histotype-specific copy-number alterations in ovarian cancer.

Authors:  Ruby Yunju Huang; Geng Bo Chen; Noriomi Matsumura; Hung-Cheng Lai; Seiichi Mori; Jingjing Li; Meng Kang Wong; Ikuo Konishi; Jean-Paul Thiery; Liang Goh
Journal:  BMC Med Genomics       Date:  2012-10-18       Impact factor: 3.063

Review 10.  DDX3, a potential target for cancer treatment.

Authors:  Guus Martinus Bol; Min Xie; Venu Raman
Journal:  Mol Cancer       Date:  2015-11-05       Impact factor: 27.401

View more
  10 in total

1.  Molecular signatures of X chromosome inactivation and associations with clinical outcomes in epithelial ovarian cancer.

Authors:  Stacey J Winham; Nicholas B Larson; Sebastian M Armasu; Zachary C Fogarty; Melissa C Larson; Brian M McCauley; Chen Wang; Kate Lawrenson; Simon Gayther; Julie M Cunningham; Brooke L Fridley; Ellen L Goode
Journal:  Hum Mol Genet       Date:  2019-04-15       Impact factor: 6.150

2.  X chromosome inactivation in the human placenta is patchy and distinct from adult tissues.

Authors:  Tanya N Phung; Kimberly C Olney; Brendan J Pinto; Michelle Silasi; Lauren Perley; Jane O'Bryan; Harvey J Kliman; Melissa A Wilson
Journal:  HGG Adv       Date:  2022-05-23

3.  Preferential X Chromosome Inactivation as a Mechanism to Explain Female Preponderance in Myasthenia Gravis.

Authors:  Vanessa Nicolì; Silvia Maria Tabano; Patrizia Colapietro; Michelangelo Maestri; Roberta Ricciardi; Andrea Stoccoro; Laura Fontana; Melania Guida; Monica Miozzo; Fabio Coppedè; Lucia Migliore
Journal:  Genes (Basel)       Date:  2022-04-15       Impact factor: 4.141

4.  A new sex-specific underlying mechanism for female schizophrenia: accelerated skewed X chromosome inactivation.

Authors:  Xinzhu Zhang; Yuhong Li; Lei Ma; Guofu Zhang; Min Liu; Chuanyue Wang; Yi Zheng; Rena Li
Journal:  Biol Sex Differ       Date:  2020-07-17       Impact factor: 5.027

5.  Cross-species examination of X-chromosome inactivation highlights domains of escape from silencing.

Authors:  Bradley P Balaton; Oriol Fornes; Wyeth W Wasserman; Carolyn J Brown
Journal:  Epigenetics Chromatin       Date:  2021-02-17       Impact factor: 4.954

6.  Bayesian modeling of skewed X inactivation in genetically diverse mice identifies a novel Xce allele associated with copy number changes.

Authors:  Kathie Y Sun; Daniel Oreper; Sarah A Schoenrock; Rachel McMullan; Paola Giusti-Rodríguez; Vasyl Zhabotynsky; Darla R Miller; Lisa M Tarantino; Fernando Pardo-Manuel de Villena; William Valdar
Journal:  Genetics       Date:  2021-05-17       Impact factor: 4.562

Review 7.  Improving clinical outcomes through attention to sex and hormones in research.

Authors:  Michelle M Mielke; Virginia M Miller
Journal:  Nat Rev Endocrinol       Date:  2021-07-27       Impact factor: 47.564

8.  Transmission of X-linked Ovarian Cancer: Characterization and Implications.

Authors:  John Lewis Etter; Kirsten Moysich; Shaun Kohli; Shashikant Lele; Kunle Odunsi; Kevin H Eng
Journal:  Diagnostics (Basel)       Date:  2020-02-07

9.  Inferring genes that escape X-Chromosome inactivation reveals important contribution of variable escape genes to sex-biased diseases.

Authors:  Renan Sauteraud; Jill M Stahl; Jesica James; Marisa Englebright; Fang Chen; Xiaowei Zhan; Laura Carrel; Dajiang J Liu
Journal:  Genome Res       Date:  2021-08-23       Impact factor: 9.043

10.  Contribution of genetic and epigenetic changes to escape from X-chromosome inactivation.

Authors:  Bradley P Balaton; Carolyn J Brown
Journal:  Epigenetics Chromatin       Date:  2021-06-29       Impact factor: 4.954

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.